| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.007 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.094 | 0.007 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.091 | 0.008 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.008 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.009 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.009 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | 0.31 | 0.01 |